In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Jinmei JinState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0000-0002-5948-5001 Xiao-Hui LiangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0009-0004-3922-8472 Yue YanState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0009-0008-3289-2345 Qingyi XiongState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0009-0001-3957-2896 Dong LuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0000-0001-9443-697X Hongzhuan ChenState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0000-0002-5367-2949 Ye WuState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0000-0003-4974-0774 Xin LuanState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID 0000-0003-3674-256X Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with a high propensity for bone metastasis and limited treatment options. Although many proteins drive metastasis, most remain inaccessible to conventional small-molecule drugs due to lack of suitable binding sites, prompting interest in upstream RNA regulators. Using integrative bioinformatics and machine learning, we identified hsa-microRNA-301a-3p as a central regulator of TNBC bone metastasis. However, current nucleic acid-based therapies are limited by instability and inefficient delivery. To overcome these challenges, we designed a ribonuclease-targeting chimera (RIBOTAC) that recruits endogenous RNase L to degrade the primary transcript pri-microRNA-301a. The resulting RIBOTAC efficiently reduced hsa-microRNA-301a-3p levels, restored NEDD4L expression, and promoted degradation of the oncogenic protein YAP, thereby suppressing TNBC bone metastasis. These findings identify hsa-microRNA-301a-3p as a key driver and demonstrate RNA-targeted degradation as a therapeutic strategy in TNBC bone metastasis.
Indexed as
Bone NeoplasmsEndoribonucleasesMicroRNAsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceNedd4 Ubiquitin Protein LigasesEndoribonucleasesMicroRNAsMIRN301A microRNA, humanNedd4 Ubiquitin Protein Ligases
Identifiers
PMID42647607
PMCPMC13510613
What Socratic holds
Textmetadata
Read underepoch 390